Results vary, and honest expectations are part of good medicine
This drug first came on the market in 2012
Explore Use our free BMI Calculator online to estimate your Body Mass Index from home and better understand your weight category, obesity risk, and possible medical weight loss options
Legitimate compounding pharmacies test their products for potency, sterility, and endotoxins
References SURMOUNT-5 head-to-head trial (NEJM, May 2025) summary via American College of Cardiology: SURPASS-2 primary publication (NEJM, 2021): Eli Lilly SURMOUNT-1 results announcement (NEJM data): Insights into the Mechanism of Action of Tirzepatide (PMC narrative review): Tirzepatide is an imbalanced and biased dual GIP/GLP-1 receptor agonist (PMC): SURMOUNT-5 GI tolerability / discontinuation data (Applied Clinical Trials, tctmd, DiabetesontheNet coverage): SURMOUNT-1 to -4 GI tolerability (Rubino 2025, Diabetes Obesity & Metabolism): Community sentiment context Reddit GLP-1 side-effect analysis and comparative meta-analyses (PMC): Research Use Only Notice: The content on this page is provided for informational and educational purposes only
Following medical advice guides patients through each step, from the first dose to weekly check-ins
